321 related articles for article (PubMed ID: 33746084)
21. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis.
Kulkarni SR; Soroka CJ; Hagey LR; Boyer JL
Hepatology; 2016 Dec; 64(6):2151-2164. PubMed ID: 27639250
[TBL] [Abstract][Full Text] [Related]
22. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
23. PGC1α deficiency reverses cholestasis-induced liver injury via attenuating hepatic inflammation and promoting bile duct remodeling.
Li D; Ye C; Liu P; Sun T; Qin Y; Wan X
Acta Histochem; 2023 Dec; 125(8):152097. PubMed ID: 37813066
[TBL] [Abstract][Full Text] [Related]
24. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
[TBL] [Abstract][Full Text] [Related]
25. Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis.
Glaser F; John C; Engel B; Höh B; Weidemann S; Dieckhoff J; Stein S; Becker N; Casar C; Schuran FA; Wieschendorf B; Preti M; Jessen F; Franke A; Carambia A; Lohse AW; Ittrich H; Herkel J; Heeren J; Schramm C; Schwinge D
J Hepatol; 2019 Oct; 71(4):783-792. PubMed ID: 31207266
[TBL] [Abstract][Full Text] [Related]
26. A novel murine model of reversible bile duct obstruction demonstrates rapid improvement of cholestatic liver injury.
Taylor SA; Yeap XY; Wang JJ; Gromer KD; Kriegermeier A; Green RM; Zhang ZJ
Physiol Rep; 2020 May; 8(10):e14446. PubMed ID: 32441483
[TBL] [Abstract][Full Text] [Related]
27. MiR-200c-3p targets SESN1 and represses the IL-6/AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis.
Song Y; Tran M; Wang L; Shin DJ; Wu J
Lab Invest; 2022 May; 102(5):485-493. PubMed ID: 34880414
[TBL] [Abstract][Full Text] [Related]
28. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
29. Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation.
Gehrke N; Nagel M; Straub BK; Wörns MA; Schuchmann M; Galle PR; Schattenberg JM
Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G319-G333. PubMed ID: 29191940
[TBL] [Abstract][Full Text] [Related]
30. Nerve growth factor induced farnesoid X receptor upregulation modulates autophagy flux and protects hepatocytes in cholestatic livers.
Tsai MS; Lee HM; Huang SC; Sun CK; Chiu TC; Chen PH; Lin YC; Hung TM; Lee PH; Kao YH
Arch Biochem Biophys; 2020 Mar; 682():108281. PubMed ID: 32001246
[TBL] [Abstract][Full Text] [Related]
31. Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury.
Shearn CT; Anderson AL; Miller CG; Noyd RC; Devereaux MW; Balasubramaniyan N; Orlicky DJ; Schmidt EE; Sokol RJ
Hepatol Commun; 2023 Jan; 7(1):e0020. PubMed ID: 36633484
[TBL] [Abstract][Full Text] [Related]
32. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.
Li X; Liu R; Huang Z; Gurley EC; Wang X; Wang J; He H; Yang H; Lai G; Zhang L; Bajaj JS; White M; Pandak WM; Hylemon PB; Zhou H
Hepatology; 2018 Aug; 68(2):599-615. PubMed ID: 29425397
[TBL] [Abstract][Full Text] [Related]
33. Cholestasis downregulate hepcidin expression through inhibiting IL-6-induced phosphorylation of signal transducer and activator of transcription 3 signaling.
Huang YH; Chuang JH; Yang YL; Huang CC; Wu CL; Chen CL
Lab Invest; 2009 Oct; 89(10):1128-39. PubMed ID: 19652645
[TBL] [Abstract][Full Text] [Related]
34. Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.
Blokker BA; Maijo M; Echeandia M; Galduroz M; Patterson AM; Ten A; Philo M; Schungel R; Gutierrez-de Juan V; Halilbasic E; Fuchs C; Le Gall G; Milkiewicz M; Milkiewicz P; Banales JM; Rushbrook SM; Mato JM; Trauner M; Müller M; Martínez-Chantar ML; Varela-Rey M; Beraza N
Hepatology; 2019 Feb; 69(2):699-716. PubMed ID: 30229970
[TBL] [Abstract][Full Text] [Related]
35. miR-194 Up-Regulates Cholesterol 7 Alpha-Hydroxylase Expression via β-Catenin Signaling and Aggravates Cholestatic Liver Diseases.
Chen PC; Hsu CP; Wang SY; Wu TY; Lin YJ; Chen YT; Hsu SH
Am J Pathol; 2023 Jun; 193(6):755-768. PubMed ID: 36868469
[TBL] [Abstract][Full Text] [Related]
36. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation.
Jang JH; Rickenbacher A; Humar B; Weber A; Raptis DA; Lehmann K; Stieger B; Moritz W; Soll C; Georgiev P; Fischer D; Laczko E; Graf R; Clavien PA
Hepatology; 2012 Jul; 56(1):209-18. PubMed ID: 22290718
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice.
Huang YH; Yang YL; Huang FC; Tiao MM; Lin YC; Tsai MH; Wang FS
Exp Biol Med (Maywood); 2018 Jan; 243(1):13-21. PubMed ID: 29105510
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
Kimura M; Nishikawa K; Osawa Y; Imamura J; Yamaji K; Harada K; Yatsuhashi H; Murata K; Miura K; Tanaka A; Kanto T; Kohara M; Kamisawa T; Kimura K
Hepatol Commun; 2022 Oct; 6(10):2732-2747. PubMed ID: 35855613
[TBL] [Abstract][Full Text] [Related]
39. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
[TBL] [Abstract][Full Text] [Related]
40. Blockade of neutrophil extracellular trap components ameliorates cholestatic liver disease in Mdr2 (Abcb4) knockout mice.
Hintermann E; Tondello C; Fuchs S; Bayer M; Pfeilschifter JM; Taubert R; Mollenhauer M; Elferink RPJO; Manns MP; Christen U
J Autoimmun; 2024 Jun; 146():103229. PubMed ID: 38653165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
